| Asthma
Breo Ellipta vs Advair HFA
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Breo Ellipta vs Advair Hfa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAdvair Hfa has a higher rate of injection site reactions vs Breo Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Advair Hfa but not Breo Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breo Ellipta
Advair Hfa
At A Glance
Oral inhalation
Once daily
ICS/LABA combination
Oral inhalation
Twice daily
ICS/LABA combination
Indications
- Chronic Obstructive Airway Disease
- Asthma
- Asthma
Dosing
Chronic Obstructive Airway Disease 1 actuation of BREO ELLIPTA 100/25 mcg once daily by oral inhalation; use a short-acting beta2-agonist for breakthrough symptoms between doses.
Asthma Adults >=18 years: 1 actuation of BREO ELLIPTA 100/25 mcg or 200/25 mcg once daily by oral inhalation; pediatric patients 12-17 years: 1 actuation of BREO ELLIPTA 100/25 mcg once daily; pediatric patients 5-11 years: 1 actuation of BREO ELLIPTA 50/25 mcg once daily; maximum dose is 1 inhalation of BREO ELLIPTA 200/25 mcg once daily.
Asthma 2 oral inhalations (45 mcg/21 mcg, 115 mcg/21 mcg, or 230 mcg/21 mcg) twice daily approximately 12 hours apart; starting strength based on asthma severity; maximum 2 inhalations of 230 mcg/21 mcg twice daily.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, vilanterol, or any excipient
- Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required
- Hypersensitivity to any ingredient of ADVAIR HFA
Adverse Reactions
Most common (>=3%) nasopharyngitis, upper respiratory tract infection, oropharyngeal candidiasis, headache, back pain, pneumonia, bronchitis, sinusitis, cough, arthralgia, influenza, pharyngitis, pyrexia
Serious serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia, immunosuppression, hypercorticism, adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, growth effects, glaucoma, cataracts
Postmarketing palpitations, tachycardia, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, nervousness, paradoxical bronchospasm
Most common (>=3%) Upper respiratory tract infection, throat irritation, headache, nausea and vomiting, musculoskeletal pain, upper respiratory inflammation, viral respiratory infection, hoarseness/dysphonia, dizziness, viral gastrointestinal infection, gastrointestinal signs and symptoms, muscle pain
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD patients, immunosuppression and risk of infections, hypercorticism and adrenal suppression, cardiovascular and CNS effects, reduction in bone mineral density, growth effects, glaucoma and cataracts
Postmarketing Arrhythmias, hypertension, ventricular tachycardia, Cushing's syndrome, osteoporosis, cataracts, glaucoma, anaphylaxis, esophageal candidiasis, paradoxical bronchospasm, agitation, depression
Pharmacology
Breo Ellipta combines fluticasone furoate, a synthetic trifluorinated ICS that inhibits inflammation via glucocorticoid receptor activation, with vilanterol, a LABA that relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors and increasing intracellular cyclic AMP.
ADVAIR HFA combines fluticasone propionate, a synthetic trifluorinated corticosteroid with broad anti-inflammatory activity via glucocorticoid receptor binding, and salmeterol, a selective long-acting beta2-adrenoceptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating adenyl cyclase to increase cyclic AMP levels.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breo Ellipta
- Covered on 5 commercial plans
- PA (3/12) · Step Therapy (0/12) · Qty limit (10/12)
Advair Hfa
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (12/12)
UnitedHealthcare
Breo Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Advair Hfa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (1/8) · Qty limit (5/8)
Humana
Breo Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Advair Hfa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breo Ellipta.
No savings programs available for Advair Hfa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Breo ElliptaView full Breo Ellipta profile
Advair HfaView full Advair Hfa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.